Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03584633 · ClinicalTrials.gov registry record · Phase 4

Effect of Exercise on Indocyanine Green (ICG) Lymphography Imaging

A Phase 4 study, sponsored by University of Iowa.

Completed
Registry status
Phase 4
Development phase
9
Enrollment target

NCT03584633: Completed Phase 4 study, sponsored by University of Iowa.

NCT03584633 is a Phase 4 study that has completed, run by University of Iowa. The registered enrollment target is 9 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03584633, a Phase 4 study, has completed, sponsored by University of Iowa.

COMPLETED
Registry status
Phase 4
Development phase
9 participants
Enrollment target

Study Summary

Indocyanine Green (ICG) lymphography is a relatively new imaging technique that allows for quick visualization of superficial lymph flow in real-time, without radiation exposure. This imaging is useful for diagnosing and assessing lymphedema. ICG lymphography has a higher sensitivity and specificity than lymphoscintigraphy, the current gold standard imaging device for lymphedema. ICG lymphography precisely and reliably diagnoses, tracks, and stages lymphedema severity, ranging from subclinical or early lymphedema to more advanced cases. The ICG contrast dye used to visualize the lymphatic system takes approximately six hours to plateau. Therefore, patients must wait six hours between their initial and delayed scans. The purpose of this study is to determine if exercising on a Nu-step device between ICG initial and delayed scans would shorten the period of time a patient had to spend at the hospital on the day of their ICG lymphography. The general procedures for this involve (after selecting subjects, consenting subjects, educating the subject on the protocol, along with other appropriate measures): * Taking baseline vitals (HR \& SpO2) and limb circumference measurements * 5-minute period of time to acquaint subject with the exercise equipment (Nu-Step) at any level of exertion * injection of contrast agent to allow for visualization of the superficial lymphatic system by a qualified nurse * Initial scan * A 5-minute period of exercise at "moderate" level of exercise (This correlates to the rating of perceived exertion levels of 12-13; All exercise periods should be at this level and will be monitored by a provider) * Second scan \& vitals * 5-minute period of exercise * Third scan \& vitals o Continue 5-minute exercise period followed by scan \& vitals until disease pattern emerges \* Exercise for 5 minutes then scan and vitals until images reach steady state for two consecutive scans * Final vitals (HR \& SpO2) \* Repeat scan every 1 hour until the no

Primary Outcome

After subjects exercise, this outcome will be measured by indocyanine green lymphography scans, a non-radioactive scan that visualizes the lymphatic system

Interventions

  • DRUG Indocyanine Green

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2019-04-15
Est. Completion 2019-12-31
Phase Phase 4
University of Iowa

228 total trials

What the finished NCT03584633 record still lists

NCT03584633 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 1 intervention - of which Indocyanine Green is the first listed.

NCT03584633 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03584633 about?

NCT03584633 is a clinical study titled "Effect of Exercise on Indocyanine Green (ICG) Lymphography Imaging". Indocyanine Green (ICG) lymphography is a relatively new imaging technique that allows for quick visualization of superficial lymph flow in real-time, without radiation exposure. This imaging is useful for diagnosing and assessing lymphedema. ICG lymphography has a higher sensitivity and specificity...

What is the current status of trial NCT03584633?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2019-04-15. Estimated completion is 2019-12-31.

What interventions are being tested in trial NCT03584633?

The interventions under investigation include: Indocyanine Green (DRUG).

Who is sponsoring clinical trial NCT03584633?

This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03584633's enrollment target sits among peer trials

9 1968th of 2000 higher than 29 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03584633, the US trial registry maintained by the National Library of Medicine. NCT03584633 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.